Clinical and translational results from REVOLUTION cohorts A (nivolumab plus ipilimumab plus chemotherapy) and B (hydroxychloroquine plus ipilimumab plus chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma.

被引：0
|
作者：
O'Reilly, Eileen M.
Wainberg, Zev A.
Fisher, George A., Jr.
Wolff, Robert A.
Ko, Andrew H.
O'Hara, Mark H.
Spencer, Christine N.
Yu, Jia Xin
Da Silva, Diane M.
Padron, Lacey J.
Lyman, Jaclyn P.
Moore, Jonni S.
Peng, Brandon
Hoos, William
O'Donnell-Tormey, Jill
Boffo, Silvia
Dugan, Ute
Cabanski, Christopher R.
Amaravadi, Ravi K.
Vonderheide, Robert H.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[3] Stanford Univ, Stanford, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[5] Univ Calif San Francisco, San Francisco, CA USA
[6] Univ Penn, Philadelphia, PA USA
[7] Parker Inst Canc Immunotherapy, San Francisco, CA USA
[8] 1440 Fdn, Silicone Valley, CA USA
[9] Canc Res Inst, New York, NY USA
[10] Bristol Myers Squibb, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4137
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
    Robert, Caroline
    Thomas, Luc
    Bondarenko, Igor
    O'Day, Steven
    Weber, Jeffrey
    Garbe, Claus
    Lebbe, Celeste
    Baurain, Jean-Francois
    Testori, Alessandro
    Grob, Jean-Jacques
    Davidson, Neville
    Richards, Jon
    Maio, Michele
    Hauschild, Axel
    Miller, Wilson H., Jr.
    Gascon, Pere
    Lotem, Michal
    Harmankaya, Kaan
    Ibrahim, Ramy
    Francis, Stephen
    Chen, Tai-Tsang
    Humphrey, Rachel
    Hoos, Axel
    Wolchok, Jedd D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26): : 2517 - 2526
  • [2] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF TREMELIMUMAB plus DURVALUMAB plus CHEMOTHERAPY VS PEMBROLIZUMAB plus CHEMOTHERAPY AND NIVOLUMAB plus IPILIMUMAB plus CHEMOTHERAPY FOR FIRST-LINE METASTATIC NSCLC
    Johal, Sukhvinder
    Miranda, Miguel
    Sarbajna, Tina
    Shi, Xiaojin
    Greystoke, Alastair
    Johnson, Melissa
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A608 - A608
  • [3] Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer
    Feldman, Hope
    Sepesi, Boris
    Leung, Cheuk H.
    Lin, Heather
    Weissferdt, Annikka
    Pataer, Apar
    William Jr, William N.
    Walsh, Garrett L.
    Rice, David C.
    Roth, Jack A.
    Mehran, Reza J.
    Hofstetter, Wayne L.
    Antonoff, Mara B.
    Rajaram, Ravi
    Gibbons, Don L.
    Lee, J. Jack
    Heymach, John V.
    Vaporciyan, Ara A.
    Swisher, Stephen G.
    Cascone, Tina
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 167 (04):
  • [4] A phase II pilot trial of nivolumab plus albumin bound paclitaxel plus paricalcitol plus cisplatin plus gemcitabine (NAPPCG) in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma.
    Borazanci, Erkut Hasan
    Jameson, Gayle S.
    Borad, Mitesh J.
    Ramanathan, Ramesh K.
    Korn, Ronald Lee
    Caldwell, Lana
    Ansaldo, Karen
    Hendrickson, Kristin
    Von Hoff, Daniel D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [5] Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
    Kohei Shitara
    Jaffer A. Ajani
    Markus Moehler
    Marcelo Garrido
    Carlos Gallardo
    Lin Shen
    Kensei Yamaguchi
    Lucjan Wyrwicz
    Tomasz Skoczylas
    Arinilda Campos Bragagnoli
    Tianshu Liu
    Mustapha Tehfe
    Elena Elimova
    Ricardo Bruges
    Thomas Zander
    Sergio de Azevedo
    Ruben Kowalyszyn
    Roberto Pazo-Cid
    Michael Schenker
    James M. Cleary
    Patricio Yanez
    Kynan Feeney
    Michalis V. Karamouzis
    Valerie Poulart
    Ming Lei
    Hong Xiao
    Kaoru Kondo
    Mingshun Li
    Yelena Y. Janjigian
    [J]. Nature, 2022, 603 : 942 - 948
  • [6] Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
    Shitara, Kohei
    Ajani, Jaffer A.
    Moehler, Markus
    Garrido, Marcelo
    Gallardo, Carlos
    Shen, Lin
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda Campos
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Bruges, Ricardo
    Zander, Thomas
    de Azevedo, Sergio
    Kowalyszyn, Ruben
    Pazo-Cid, Roberto
    Schenker, Michael
    Cleary, James M.
    Yanez, Patricio
    Feeney, Kynan
    Karamouzis, Michalis, V
    Poulart, Valerie
    Lei, Ming
    Xiao, Hong
    Kondo, Kaoru
    Li, Mingshun
    Janjigian, Yelena Y.
    [J]. NATURE, 2022, 603 (7903) : 942 - +
  • [7] Discussion to: Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer
    Feldman, Hope
    Bott, Matthew
    Mehran, Reza J.
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 167 (04): : 1454 - 1455
  • [8] Nivolumab plus chemotherapy or ipilimumab for advanced oesophageal squamous cell carcinoma
    Jordan Hindson
    [J]. Nature Reviews Gastroenterology & Hepatology, 2022, 19 : 216 - 216
  • [9] Nivolumab plus chemotherapy or ipilimumab for advanced oesophageal squamous cell carcinoma
    Hindson, Jordan
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2022, 19 (04) : 216 - 216
  • [10] Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report
    Kunimatsu, Yusuke
    Kano, Yukari
    Tsutsumi, Rei
    Sato, Izumi
    Tanimura, Mai
    Tanimura, Keiko
    Takeda, Takayuki
    [J]. RESPIROLOGY CASE REPORTS, 2023, 11 (04):
12345